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Abstract
Background: The criteria for defining severe malaria have evolved over the last 20 years. We aimed to assess the
strength of association of death with features currently characterizing severe malaria through a systematic review
and meta-analysis.
Method: Electronic databases (Medline, Embase, Cochrane Database of Systematic Reviews, Thomson Reuters Web
of Knowledge) were searched to identify publications including African children with severe malaria. PRISMA
guidelines were followed. Selection was based on design (epidemiological, clinical and treatment studies),
setting (Africa), participants (children < 15 years old with severe malaria), outcome (survival/death rate), and
prognostic indicators (clinical and laboratory features). Quality assessment was performed following the criteria
of the 2011 Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2). Odds ratios (ORs) were calculated
for each study and prognostic indicator, and, when a test was assessed in at least two studies, pooled
estimates of ORs were computed using fixed- or random-effects meta-analysis.
Results: A total of 601 articles were identified and screened and 30 publications were retained. Features with
the highest pooled ORs were renal failure (5.96, 95% CI 2.93–12.11), coma score (4.83, 95% CI 3.11–7.5), hypoglycemia
(4.59, 95% CI 2.68–7.89), shock (4.31, 95% CI 2.15–8.64), and deep breathing (3.8, 95% CI 3.29–4.39). Only half of the
criteria had an OR > 2. Features with the lowest pooled ORs were impaired consciousness (0.58, 95% CI 0.25–1.37),
severe anemia (0.76, 95% CI 0.5– 1.13), and prostration (1.12, 95% CI 0.45–2.82).
Conclusion: The findings of this meta-analysis show that the strength of association between the criteria
defining severe malaria and death is quite variable for each clinical and/or laboratory feature (OR ranging
from 0.58 to 5.96). This ranking allowed the identification of features weakly associated with death, such as
impaired consciousness and prostration, which could assist to improve case definition, and thus optimize
antimalarial treatment.
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Background
Severe malaria accounted for approximately 2 million
out of 207 million estimated malaria cases in 2012 [1].
In areas with intense and stable transmission, children
under the age of 5 years carry the heaviest burden, espe-
cially in the sub-Saharan region [2]. Although a correct
and prompt diagnosis of severe malaria is crucial for
prescribing appropriate therapy, and thus for reducing
mortality, the parenteral administration of first-line
treatment often remains a challenge in resource poor
settings. Improved targeting of children who would
benefit most from parenteral treatment rather than oral
treatment would help the overall management of malaria
cases.
A child is diagnosed with severe malaria when asexual
P. falciparum parasitemia is detected in the peripheral
blood smear or confirmed by a rapid diagnostic test,
there is no other cause for its symptoms, and at least one of
impaired consciousness, respiratory distress, multiple con-
vulsions, prostration, shock, pulmonary edema, abnormal
bleeding, jaundice, severe anemia, hypoglycemia, acidosis,
hyperlactatemia, renal impairment, or hyperparasitemia is
present. These criteria reflect the definition of severe mal-
aria established by the World Health Organization (WHO)
in 2000, according to which any child with positive blood
parasitemia and at least one of abovementioned criteria is
qualified to receive parenteral treatment [3].
In recent years, a decrease in the case fatality rate of
malaria has been observed [4]. The reasons for this
improvement are not entirely clear, but introduction of
drugs with increased efficacy [5, 6] and effective control
programs [7] have certainly played a crucial role. A
reduction in the case fatality rate of severe malaria has
also been documented in controlled trials [5, 6]. A poten-
tial confounder for this observed reduction may be related
to a selection bias due to a shift in severe malaria case
definition. In 1990, the WHO set the criteria for a strict
definition of severe malaria for research and epidemio-
logical purposes [8]. In 2000, new neurological criteria,
i.e., prostration and impaired consciousness, were intro-
duced into the definition [9], and recent works have relied
on a wider pragmatic case definition. For example, the
Severe Malaria in African Children (SMAC) studies in-
cluded children with P. falciparum detected on blood
smear and classified as “being severely ill enough to be
hospitalized”, without further specifications [10].
In this context, we conducted a systematic review and
meta-analysis to better understand the prognostic value
of clinical and laboratory findings used to diagnose
severe malaria in African children. This assessment was
aimed at refining the commonly employed definition of
severe malaria to then explore the possibility to define
‘moderately severe malaria’ cases that could benefit from
much more accessible oral treatment.
Methods
Search strategy and sources
We performed a systematic literature search using
Medline, Embase, Cochrane Database of Systematic
Reviews, and Thomson Reuters Web of Knowledge. Study
selection followed the Preferred Reporting Items for Sys-
temic Reviews and Meta-Analyses (PRISMA) guidelines
[11]. The first search was undertaken in January 2014,
with an update in February 2015. We searched Medline
and Embase using Medical Subject Headings and
subheadings used for indexing articles. We combined the
following terms: “malaria/complications OR malaria/mor-
tality” AND “treatment outcome” AND “infant, newborn
OR infant OR child OR adolescent”. In the Cochrane
Database, we looked for the words “malaria and children”
in the main title of the review. We searched the Thomson
Reuters Web of Knowledge using the words “malaria
child”, “Africa”, “mortality” and “complications”. We did
not put any language or time restrictions on the search
and we expanded it by examining the reference list of the
selected studies. Additionally, we used three landmark
articles [10, 12, 13] on severe malaria in African children
to search for citations closely related to the selected article
using the PubMed option “Related citations”.
Inclusion and exclusion criteria
Studies reporting clinical and laboratory variables, includ-
ing at least 100 children aged < 15 years who were
diagnosed with severe malaria according to the WHO def-
initions, and which allowed reconstructing of two-by-two
tables made up of outcome (survival/death) and presence/
absence of prognostic indicator, were included in this
review. Controlled trials, non-controlled trials, cohort
studies, case control studies and case series, both pro-
spective and retrospective, were considered. When neces-
sary, authors were contacted to obtain data to construct
two-by-two tables. Two independent reviewers (BG and
JD) conducted this search. Two [5, 10] of the included
studies served as reference publications for other enclosed
publications, although no direct prognostic indicators
could be extracted. Three selected studies [13–15] consid-
ered either partial or the whole population included
originally in the study comparing artesunate with quinine
in severe malaria treatment in Africa (known as the
AQUAMAT study). In this case, the study with a greater
number of study subjects with available clinical or labora-
tory features associated with death was selected. Two arti-
cles [16, 17] encompassed the same study population
though they focused on distinct clinical or laboratory vari-
ables; thus, both of them were retained. In addition, 356
out of 2901 children enrolled in a study in The Gambia
[18] also participated in the AQUAMAT study, which
leads to duplication of the subjects included in these two
large studies.
Sypniewska et al. BMC Medicine  (2017) 15:147 Page 2 of 17
Finally, in view of the size of the comprised popula-
tion, we also considered data from the SMAC studies
[19] in our systematic review, although study inclusion
criteria did not fully comply with the strict WHO defin-
ition of severe malaria. Therefore, we performed separ-
ate analyses with and without the SMAC studies.
Quality assessment
Quality of selected studies and their risk of biases were
assessed by applying the 2011 revised version of the
Quality Assessment of Diagnostic Accuracy Studies
(QUADAS-2) tool [20], which was adjusted to the particu-
larity of this review following the recommendation of the
Cochrane Collaboration (details in Additional file 1) [21].
When the patients’ inclusion criteria differed from the
WHO criteria, we reported in the methodological quality
assessment that there were great concerns about the
applicability of the results to the research question.
Regarding prognostic indicators, clinical and laboratory
features were assessed separately. Furthermore, any re-
ported death was considered as a reference standard.
Studies including less than 80% of enrolled patients were
labeled as highly biased. Quality assessment was per-
formed by one reviewer (PS) and checked by a second re-
viewer (BG). Any disagreements were resolved through
discussion and consensus.
Data extraction
Data on clinical features among children who survived
or died were extracted by one reviewer (PS) using a
standardized data extraction form and checked by the
second (JD), as well as on random basis by the third
(BG) reviewer. Information on characteristics (design,
year of publication, study country, healthcare setting),
study population (size, age range, mortality, inclusion
and exclusion criteria), and prognostic indicators was
gathered. Any identified errors were re-examined and
corrected accordingly.
Statistical analysis
A two-by-two table including crossing variables, index
test (0,1) and death (0,1), was constructed for each prog-
nostic indicator. Odds ratios (ORs) were calculated to
measure the association of each prognostic indicator with
death. When a prognostic indicator was assessed in at
least two studies, pooled estimates of ORs were calculated.
A random effects meta-analysis was performed in the case
of a significant heterogeneity among studies (P < 0.05).
Otherwise, the fixed-effect approach was preferred. Metan
command in STATA version 12 was used to perform these
meta-analyses [22]. Results for all predictors were summa-
rized in a Forrest plot, ordering markers from the least to
the most strongly associated with death. The size of each
predictor’s box is proportional to the global sample size of
studies involved in the corresponding summary ORs. Two
separate analyses were conducted; one enclosing add-
itional findings derived from the SMAC studies and
one without it, covering studies that referred strictly
to the definition of WHO as diagnosis criteria. Prog-
nostic indicators with definitive thresholds and few
without single definition (acidosis, hyperparasitemia,
renal failure, respiratory distress, shock) were pooled
for the usage of this analysis. The combination of
symptoms was not analyzed in this systematic review
due to unavailability of individual records.
Results
A total of 601 studies were identified and screened in
the systematic database search. Through the selection
process presented in the flow diagram (Fig. 1), 30 titles
[5, 10, 13–19, 23–43] published between 1994 and 2014
were selected and used to identify predictors; 28 were
finally included in the meta-analysis (no direct data
could be extracted from two referral studies). Overall,
90% of eligible studies were reported in English and
10% in French. The characteristics of the studies are
outlined in Table 1. The summary of quality assessment of
analyzed studies, according to the QUADAS-2 tool, is
presented in Table 2. The detailed analysis of each study
according to the QUADAS-2 tool was captured in
Additional file 2.
A total of 36 different prognostic indicators associated
with death due to severe malaria were identified in 30
studies. The number of predictors of mortality evaluated
per study ranged from 1 to 19 (median 6.5, interquartile
range 3–11). Out of 36 identified prognostic indicators,
18 corresponded with the clinical criteria of severe
malaria established by the WHO. Two forest plots dis-
playing pooled estimates of ORs with 95% confidence
intervals (CI) calculated for 17 and 18 prognostic indica-
tors included in the WHO definition of severe malaria
are captured in Figs. 2 and 3, respectively. Definitions
and further characteristics of the analyzed prognostic
indicators are assembled in Table 3.
Prognostic indicators with the strongest association with
death included renal failure (5.96, 95% CI 2.93–12.11),
coma (4.83, 95% CI 3.11–7.5), hypoglycemia (4.59, 95% CI
2.68–7.89), shock (4.31, 95% CI 2.15–8.64), and deep
breathing (3.8, 95% CI 3.29–4.39). These five indicators
also had the largest CI boundaries. Respiratory distress,
while having a lower OR than the five indicators men-
tioned above, presented a narrower CI and lower CI
boundaries in line with five top indicators (3.15, 95% CI
2.79–3.35). Moreover, the results were also consistent
upon introduction of the SMAC study, with each associ-
ation being slightly larger than without the SMAC, while
the association with death of the top indicators was more
homogeneous for renal failure (5.96, 95% CI 2.93–12.11),
Sypniewska et al. BMC Medicine  (2017) 15:147 Page 3 of 17
coma (5.04, 95% CI 3.35–7.59), deep breathing 4.89
(95% CI 3.28–7.29), hypoglycemia (4.81, 95% CI
2.93–7.91), and chest indrawing (4.63, 95% CI 4.08–5.25).
The latter entered the top five indicators (in place of
shock) and also presented the lower CI boundary (>4).
Two or more convulsions (2.0, 95% CI 1.71–2.34) were
also associated with poor outcome. However, further
neurological signs, such as prostration (1.12, 95% CI
0.45–2.82) and impaired consciousness (0.58, 95% CI
0.25–1.37) were not associated with death. These results
are comparable to those after inclusion of the SMAC study,
namely convulsions (1.94, 95% CI 1.76–2.13) and prostra-
tion (1.42, 95% CI 0.39–5.14). Neither severe anemia, with
and without the SMAC studies (0.81, 95% CI 0.55–1.21
vs. 0.76, 95% CI 0.50–1.13, respectively) nor hyperpyrexia
(1.19, 95% CI 0.71–1.99) were associated with death.
Discussion
The results of the meta-analysis show that there is a large
variation in the strength of the association between the
different WHO-defined criteria of severe malaria and
death. Renal failure, coma, hypoglycemia, shock, and re-
spiratory distress represent those with the highest prog-
nostic value. These manifestations were also those with
the highest prognostic value for death in the original
paper by Marsh [12], which was supportive of the WHO
definition of severe malaria. Similarly, impaired conscious-
ness, prostration, hyperpyrexia, hyperparasitaemia, and
severe anemia were weak predictors both in the present
systematic review and in Marsh’s paper [12]. While 5039
(35.7%) of children from the enclosed studies suffered
from severe anemia, its association with death, though
widely acknowledged, was insignificant. This can possibly
be explained by the fact that anemic children receive
blood transfusion upon admission or by the lack of other
concomitant feature such as respiratory distress or neuro-
logical impairment. On the other hand, hypoglycemia,
which similarly to severe anemia could be reversed if early
detected, remains a significant marker of severity, which
can be possibly explained by its dependency on other
356 articles identified for further assessment
601 articles screened
251 excluded in initial screen of title 
and abstract
105 wrong participants
74 wrong target setting
72 wrong design
30 articles included in qualitative synthesis
135 full-text articles assessed for eligibility
28 articles 
identified from 




20 no index test
16 wrong outcome
15 wrong design 
10 wrong data reporting
2 wrong setting





3 no index test
3 duplicates  
























31 articles identified in 
update in 2015
Fig. 1 Flow diagram of the study selection process. Only the first reason for exclusion (as ordered in Appendix) is reported
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severe markers. Conditions such as malnutrition or HIV
co-infection have not been addressed in this analysis since
they are not part of the definition of severe malaria. They
are, however, very important contributors of mortality and
should definitively be considered together with other
clinical features when assessing a sick child.
The current systematic review recognizes coma (defined
as Blantyre coma scale (BCS) ≤ 2) and deep breathing as
robust prognostic factors of pediatric life-threatening mal-
aria that can simply be determined and recorded by skilled
observers in all types of settings. Deep breathing, as a
crucial respiratory sign of severe malaria, is commonly a
compensatory manifestation of underlying metabolic acid-
osis [44] and is more predictive than respiratory distress
accompanied by signs of variable severity. These findings
are nearly in line with the results from a prospective study
[12] of 1844 patients in Kenya, which identified respira-
tory distress and impaired consciousness (defined as
prostration or coma) as highly associated with death and,
except for prostration, with the Lambaréné Organ
Dysfunction Score, which combines coma, prostration,
and deep breathing [10].
Although there is no definite consensus regarding the
strongest predictors of death within the WHO clinical
definition of severe malaria, the WHO distinguished
three groups [1] classing clinical and laboratory features
of the disease in a way to facilitate appropriate treatment.
A major contrast of our results with the clinical features
included in the WHO Group 1 symptoms (prostrate but
conscious, prostrate with impaired consciousness, coma,
mild/severe respiratory distress, shock), which are sup-
posedly more severe and for which parenteral treatment is
recommended, is that a child with prostration or impaired
consciousness appears to be at a low risk of death when
compared with the presence of any other listed signs and
symptoms. One possible explanation for this unexpected
finding is that, in some studies, the definition of impaired
consciousness was less stringent than that of the WHO
(BCS < 3). Interestingly, in the differentiated group of
1289 Gabonese children, Issifou et al. [36] applied a BCS
Fig. 2 Pooled estimates of odds ratios (with 95% confidence intervals) of each predictor of mortality assessed in at least two studies (without the
Severe Malaria in African Children studies) and number of studies by each predictor. The size of each predictor’s box is proportional to the global
sample size of studies involved in the corresponding summary odds ratios. *Results calculated by fixed effects
Fig. 3 Pooled estimates of odds ratios (with 95% confidence intervals) of each predictor of mortality assessed in at least two studies (including
the Severe Malaria in African Children studies) and number of studies by each predictor. The size of each predictor’s box is proportional to the
global sample size of studies involved in the corresponding summary odds ratios. *Results calculated by fixed effects
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Table 3 Characteristics of assessed WHO prognostic indicators







Neurological symptoms and signs
Convulsions ≥2/24 hours 8197 2252 772 14.7% 2 (1.71–2.34) von Seidlein 2012 [13];
Bassat 2008 [39]; Mockenhaupt
2004 [30]; Imbert 2003 [28];
Gay-Andrieu 2005 [32];
Camara 2011 [42]; Modiano
1998 [25]
Convulsionsa ≥2/24 hours 34233 10573 1901 8.1% 1.94 (1.76–2.13) von Seidlein 2012 [13];
Bassat 2008 [39]; Mockenhaupt
2004 [30]; Imbert 2003 [28];
Gay-Andrieu 2005 [32];
Camara 2011 [42]; Modiano
1998 [25]; Kendjo 2013 [19]
Coma score BCS ≤2 16796 1675 4881 21.3% 4.83 (3.11–7.5) Krishna 1994 [23]; von
Seidlein 2012 [13]; Ranque
2008 [40]; Orimadegun 2007
[38]; Oduro 2007 [37];
Mockenhaupt 2004 [30];
Jallow 2012 [18]; Issifou
2007 [36]; Gay-Andrieu 2005
[32]; English 1997 [17];
Dzeing-Ella 2005 [31]; Bassat
2008 [39]; Camara 2011 [42];
Bronzan 2007 [35];
Orimadegun 2014 [43]
Coma scorea BCS ≤2 42832 7316 2804 20.7% 5.04 (3.35–759) Krishna 1994 [23]; von
Seidlein 2012 [13]; Ranque
2008 [40]; Orimadegun 2007
[38]; Oduro 2007 [37];
Mockenhaupt 2004 [30];
Jallow 2012 [18]; Issifou 2007
[36]; Gay-Andrieu 2005 [32];
English 1997 [17]; Dzeing-Ella
2005 [31]; Bassat 2008 [39];
Camara 2011 [42]; Bronzan
2007 [35]; Orimadegun 2014
[43]; Kendjo 2013 [19]
Impaired consciousness BCS 3–4 276 95 42 9.5% 0.58 (0.25–1.37) Gay-Andrieu 2005 [32];
Camara 2011 [42]
Prostration Cannot sit OR cannot
eat (breastfeed) OR
cannot walk OR cannot
stand up
11607 6452 1176 8.3% 1.12 (0.45–2.82) Jallow 2012 [18]; Zeidan
2005 [34]; von Seidlein 2012
[13]; Mockenhaupt 2004 [30];
Imbert 2003 [28]; Camara
2011 [42]; Bassat 2008 [39];
Assimadi 1998 [24]; Modiano
1998 [25]
Prostrationa Cannot sit OR cannot
eat (breastfeed) OR
cannot walk OR cannot
stand up
37643 22322 2305 7.0% 1.42 (0.39–5.14) Jallow 2012 [18]; Zeidan 2005
[34]; von Seidlein 2012 [13];
Mockenhaupt 2004 [30];
Imbert 2003 [28]; Camara
2011 [42]; Bassat 2008 [39];
Assimadi 1998 [24]; Modiano
1998 [25]; Kendjo 2013 [19]
Respiratory symptoms and signs
Deep breathing NR 9106 1230 965 22.2% 3.8 (3.29–4.39) von Seidlein 2012 [13];
Maitland 2003 [29]; English
1996 [16]; Varandas 2000 [26];
Jallow 2012 [18]
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Table 3 Characteristics of assessed WHO prognostic indicators (Continued)
Deep breathinga NR 32882 4049 1772 19.1% 4.89 (3.28–7.29) von Seidlein 2012 [13];
Maitland 2003 [29]; English
1996 [16]; Varandas 2000 [26];
Jallow 2012 [18]; Kendjo
2013 [19]
Indrawinga NR 26386 3137 1159 13.3% 4.63 (4.08–5.25) English 1996 [16]; Kendjo
2013 [19]
Respiratory distress Nasal flaring or costal
indrawing or accessory








15343 3729 1526 17.5% 3.15 (2.79–3.35) Jallow 2012 [18]; von Seidlein
2012 [13]; Ranque 2008 [40];
Oduro 2007 [37];
Mockenhaupt 2004 [30];
Issifou 2007 [36]; Imbert 2003
[28]; Gay Andrieu 2005 [32];
English 1996 [16]; Dzeing-Ella
2005 [31]; Camara 2011 [42];
Bassat 2008 [39]; Assimadi
1998 [24]; Varandas 2000 [26];
Modiano 1998 [25]





(BP ≥70 + CRT ≥3 s) and
decompensated (BP <70)
OR SBP <60 in
≤5-year-old children OR
SBP <80 in >5-year-old
children OR septic shock
score ≥2
7567 915 789 23.6% 4.31 (2.15–8.64) Jallow 2012 [18]; von Seidlein
2012 [13]; Mockenhaupt 2004
[30]; Maitland 2003 [29];
Imbert 2003 [28]; Assimadi
1998 [24]; Camara 2011 [42]
Abnormal
hemorrhage
NR 1349 17 199 23.5% 1.84 (0.6–5.67) Assimadi 1998 [24]; Modiano
1998 [25]
Jaundice
Jaundice 11178 599 1203 17.4% 1.65 (1.31–2.07) Jallow 2012 [18]; von Seidlein
2012 [13]; Mockenhaupt 2004
[30]; Maitland 2003 [29];
Imbert 2003 [28]; Camara
2011 [42]; Bassat 2008 [39];
Assimadi 1998 [24]
Renal symptoms and signs
Hemoglobinuria Verified by dipstick 7102 286 739 11.5% 1.84 (0.75–4.52) Mockenhaupt 2004 [30];
Imbert 2003 [28]; Assimadi
1998 [24]; Camara 2011 [42];
Orimadegun 2014 [43]; von
Seidlein 2012 [13]
Laboratory values of severe malaria in selected studies
Acidosis BE < –8 mmol/L OR base
deficit >15 OR BE
< –12 mmol/L (all)
6549 2392 646 15.1% 3.32 (1.35–8.18) Hendriksen 2012 [14];
Maitland 2005; Jallow 2012
[18]; Maitland 2003 [29];
English 1996 [16], Assimadi
1998 [24]; Orimadegun
2014 [43]
Severe anemia Hematocrit <15% or Hb
<5 g/dL
14078 5039 1406 8.2% 0.76 (0.50–1.13) Jallow 2012 [18]; Hendriksen
2012 [14]; Camara 2011 [42];
Bassat 2008 [39]; Ranque
2008 [40]; Orimadegun 2007
[38]; Mockenhaupt 2004 [30];
Maitland 2003 [29]; Issifou
2007 [36]; Gay-Andrieu 2005
[32]; Dzeing-Ella 2005 [31];
Imbert 2003 [28]; Modiano
1998 [25];
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between 3 and 4 to classify cases of moderate malaria. On
the other hand, our findings are consistent with the WHO
Group 2 clinical features (severe anemia, two or more
convulsions in past 24 hours, hemoglobinuria, jaundice),
which indicate a disease of lower severity and for which a
supervised oral therapy is recommended.
The present attempt to rank clinical features according
to their prognostic values was performed to potentially
better distinguish children that should definitely be recei-
ving parenteral treatment versus those that could be
considered for prompt oral treatment with artemisinin-
based combinations. At present, the WHO recommends
Table 3 Characteristics of assessed WHO prognostic indicators (Continued)
Severe anemiaa Hematocrit <15% or Hb
<5 g/dL
40114 10418 2535 7.4% 0.81 (0.55–1.21) Jallow 2012 [18]; Hendriksen
2012 [14]; Camara 2011 [42];
Bassat 2008 [39]; Ranque
2008 [40]; Orimadegun 2007
[38]; Mockenhaupt 2004 [30];
Maitland 2003 [29]; Issifou
2007 [36]; Gay-Andrieu 2005
[32]; Dzeing-Ella 2005 [31];
Imbert 2003 [28]; Modiano
1998 [25]; Kendjo 2013 [19]
Hyperlactatemia Lactate ≥5 mmol/L
or NR
2188 773 183 14.7% 3.76 (1.96–7.23) Jallow 2012 [18]; Krishna 1994





>4% ([32]) or parasitemia
≥250,000 p/μL ([43]) or
P. falciparum parasite
density >500,000/μL ([18])
7735 1164 873 13.2% 1.37 (1.13–1.66) Jallow 2012 [18]; Hendriksen
2012 [14]; Mockenhaupt 2004
[30]; Imbert 2003 [28];
Gay-Andrieu 2005 [32];
Orimadegun 2014 [43]
Hyperparasitemiaa Hyperparsitemia > 10%
([14]) or hyperparasitemia
>4% ([32]) or parasitemia
≥250,000 p/μL ([19, 43])
or P. falciparum parasite
density >500,000/μL ([18])
33771 6123 2002 6.5% 1.24 (1.11–1.4) Jallow 2012 [18]; Hendriksen
2012 [14]; Mockenhaupt 2004




Hypoglycemia Glucose <2.2 mmol/L 6358 37 48 16.2% 4.59 (2.68–7.89) Jallow 2012 [18]; Krishna 1994
[23]; Imbert 2003 [28];
Mockenhaupt 2004 [30];
Issifou 2007 [36]; Gay-Andrieu
2005 [32]; Dzeing-Ella 2005
[31]; Camara 2011 [42]; Bassat
2008 [39]; Modiano 1998 [25]
Hypoglycemiaa Glucose <2.2 mmol/L 31348 2933 2662 45.4% 4.81 (2.93–7.91) Jallow 2012 [18]; Krishna 1994
[23]; Imbert 2003 [28];
Mockenhaupt 2004 [30];
Issifou 2007 [36]; Gay-Andrieu
2005 [32]; Dzeing-Ella 2005
[31]; Camara 2011 [42]; Bassat
2008 [39]; Modiano 1998 [25];
Kendjo 2013 [19]
Renal failure Urine output of
<12 mL/kg/24 hours and
serum creatinine
>265 μL/L over OR plasma
creatinine >3 mg/dL
4757 32 547 40.6% 5.96 (2.93–12.11) Jallow 2012 [18]; Imbert 2003
[28]; Assimadi 1998 [24];
Modiano 1998 [25];
Orimadegun 2014 [43]
Other symptoms and signs
Hyperpyrexia >40 °C OR ≥40 °C 3946 125 919 24.8% 0.59 (0.11–3.19) Jallow 2012 [18]; Zeidan
2005 [34]; Mockenhaupt 2004
[30]; Imbert 2003 [28]
aIncluding the Severe Malaria in African Children studies.
BE base excess, BCS Blantyre coma scale, BP blood pressure, CRT capillary refill time, HB hemoglobin, NR not reported, PPV positive predictive value, SBP systolic
blood pressure
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injectable artesunate for all children with asexual forms of
P. falciparum in peripheral blood and at least one criter-
ion of severity [45]. In the light of the very different prog-
nostic values of the different features, Kopel et al. [46]
suggested that oral treatment could be a successful alter-
native for patients with a detected parasitemia and a
criterion considered as less severe, e.g., jaundice. Certainly,
all prognostic indicators that are able to be detected at the
bedside need to be searched for, and finding a low-
prognostic symptom or sign does not remove the need for
parenteral treatment if a high-prognostic one is present.
Identifying a subset of patients with moderately severe
malaria who could be safely managed with oral treatment
at the primary care level would simplify the patients’
management in settings where referral to hospital for
injectable treatment is difficult, and allow better resources
allocation. A simplified approach may be easier to imple-
ment. Already, in settings where laboratory facilities are
unavailable, the laboratory tests used to define severe mal-
aria are not considered in the classification of the disease.
This new approach should be carefully assessed in a pro-
spective multicentric clinical trial to demonstrate its safety.
To our knowledge, this is the first systematic review
and meta-analysis of predictors of death drawn from all
relevant studies of African children with strictly defined
severe malaria. Methodological quality was assessed by
using a priori adjusted and defined rules of the latest
version of QUADAS-2 tool, which allowed better evalu-
ation of risk of biases in several domains. In addition,
this review assessed the disease severity criteria used in
the SMAC studies [19]. Indeed, this represents the
largest sample size ever recruited. The fact that the re-
sults did not change much when including or not prog-
nostic indicators from the SMAC studies increases the
robustness of the findings.
The main limitation of our analysis comes from the
methodological or reporting weaknesses of some studies,
of which the most important one is the lack of reproduci-
bility of reported clinical symptoms and signs. Indeed, the
inter-observer (clinician) agreement on the assessment of
some of the signs, such as impaired consciousness or
prostration for example, can be very low. Additionally,
heterogeneity between studies regarding availability of
laboratory data, threshold used to define abnormality, and
quality of healthcare, especially with regards to blood
transfusion and management of renal failure, need to be
taken into account in results interpretation. Another limi-
tation of our review is that it did not consider combina-
tions of clinical and laboratory features of severe malaria
because of the unavailability of individual records. It has
been shown that having more than one manifestation of
severe malaria increases the risk of dying [13] and this has
to be taken into account in a child assessment of severity,
and hence in case management. Furthermore, due to lack
of data in the included studies, this meta-analysis could
not explore the impact of other concurrent complications
that do not form part of the definition of severe malaria
but are known for increasing the risk of death such as, for
example, bacteremia. In addition, since all data were
aggregated in each study, we were not able to analyze pre-
dictors by age group or sex. This should not alter much
the relevance of our findings since approximately 80%
patient population was < 5 years of age and WHO has
never considered a differential definition of severe malaria
for children and adults or male and female. Finally, studies
reporting less than 100 cases were excluded to reduce
complexity, but some of those could have brought
relevant information.
Conclusion
In conclusion, the findings of this meta-analysis show that
the strength of association between the criteria defining
severe malaria and death is quite variable for each clinical
and/or laboratory features (OR ranging from 0.58 to 5.96).
Despite the heterogeneity of entry criteria, the individual
studies provided concordant results. A ranking allowed
the identification of features weakly associated with death,
such as impaired consciousness and prostration, which
could assist to refine case definition and thus optimize
antimalarial treatment.
Appendix
Criteria for study selection
Design: Epidemiological, clinical, and treatment studies on
malaria were selected. Controlled trials, non-controlled
trials, cohort studies, case control studies, and case series,
either prospective or retrospective of 100 cases or more,
were accepted. Systematic reviews, meta-analyses, letters,
editorials, and comments were used only as a source of
reference.
Setting: Studies conducted in Africa.
Participants: Studies that included children below the age
of 15 with severe malaria according to the WHO defini-
tions, with or without modified criteria. The cases needed
to be diagnosed with parasitological confirmation defined
as parasite identification by smear or as a positive rapid
diagnostic test.
Outcome: Studies that reported death rate.
Prognostic indicators: Studies that reported clinical and
laboratory variables associated with death due to malaria.
Reference standard: any reported death from admis-
sion to end of follow-up.
Data reporting: Studies that allow the reconstruction
of two-by-two tables made up of death rate and prog-
nostic indicators of death. When necessary, authors were
contacted to obtain missing data.
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Additional file 1: Table S1. QUADAS-2 review-specific tailored tool and
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